PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A
| Status: | Completed |
|---|---|
| Conditions: | Anxiety, Chronic Pain, Depression |
| Therapuetic Areas: | Musculoskeletal, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 12/19/2018 |
| Start Date: | September 3, 2010 |
| End Date: | February 28, 2014 |
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [(11)C]NOP-1A
Background:
- A small brain protein called nociceptin/orphanin FQ peptide (NOP) receptor may be involved
in several brain diseases such as anxiety, depression, drug abuse, and seizures. Researchers
are interested in testing a new radioactive chemical that will help locate NOP receptors in
the brain during imaging studies such as positron emission tomography (PET) scans. Because
this chemical has not yet been approved by the Food and Drug Administration, it is considered
to be an experimental drug.
Objectives:
- To investigate the effectiveness of the experimental chemical [11C]NOP-1A in imaging
studies of the nociceptin/orphanin FQ peptide (NOP) receptor.
Eligibility:
- Healthy volunteers between 18 and 50 years of age who are able to have imaging studies.
Design:
- This study will involve three or four outpatient visits to the National Institutes of
Health Clinical Center. All participants will be screened with a full physical
examination, medical history, blood and urine tests, and electrocardiogram.
- Participants will be involved in one or more parts of this three-part study as directed
by study researchers. Part 1 consists of brain imaging to study how the brain responds
to the chemical. Part 2 is a whole body imaging study to evaluate how the chemical is
distributed throughout the body after being administered. Part 3 is a set of testing and
retesting scans to determine how precise the drug is in locating the NOP receptors in
the brain.
- Part 1: Participants will have a brain magnetic resonance imaging (MRI) scan. Then the
study drug will be administered and participants will have a brain PET scan. Blood
samples will be taken during the PET scan, and urine samples will be taken after the
scan. These tests will take up to 3 hours to perform.
- Part 2: Participants will have a whole body PET scan that will last a maximum of 3
hours.
- Part 3: Participants will receive the study drug and have two additional PET scans.
Blood samples will also be taken during this part.
- A small brain protein called nociceptin/orphanin FQ peptide (NOP) receptor may be involved
in several brain diseases such as anxiety, depression, drug abuse, and seizures. Researchers
are interested in testing a new radioactive chemical that will help locate NOP receptors in
the brain during imaging studies such as positron emission tomography (PET) scans. Because
this chemical has not yet been approved by the Food and Drug Administration, it is considered
to be an experimental drug.
Objectives:
- To investigate the effectiveness of the experimental chemical [11C]NOP-1A in imaging
studies of the nociceptin/orphanin FQ peptide (NOP) receptor.
Eligibility:
- Healthy volunteers between 18 and 50 years of age who are able to have imaging studies.
Design:
- This study will involve three or four outpatient visits to the National Institutes of
Health Clinical Center. All participants will be screened with a full physical
examination, medical history, blood and urine tests, and electrocardiogram.
- Participants will be involved in one or more parts of this three-part study as directed
by study researchers. Part 1 consists of brain imaging to study how the brain responds
to the chemical. Part 2 is a whole body imaging study to evaluate how the chemical is
distributed throughout the body after being administered. Part 3 is a set of testing and
retesting scans to determine how precise the drug is in locating the NOP receptors in
the brain.
- Part 1: Participants will have a brain magnetic resonance imaging (MRI) scan. Then the
study drug will be administered and participants will have a brain PET scan. Blood
samples will be taken during the PET scan, and urine samples will be taken after the
scan. These tests will take up to 3 hours to perform.
- Part 2: Participants will have a whole body PET scan that will last a maximum of 3
hours.
- Part 3: Participants will receive the study drug and have two additional PET scans.
Blood samples will also be taken during this part.
Nociceptin/orphanin FQ peptide (NOP) receptor is a new class of opioid receptor cloned in
1994 before identifying the endogenous ligand. Within a year, endogenous ligand was
identified and soon many ligands were developed and evaluated in vitro and in vivo for NOP
receptor distribution and activity. NOP receptor is widely distributed in brain, spinal cord
and in peripheral organs such as heart, lungs, kidney, intestine and liver. Being a G-protein
coupled receptor, its activation leads to changes in intracellular signal transduction
mediated by adenylyl cyclase, Ca(2+) and K(+) ion channels, mitogen-activated kinase and
phospholipase C. Based on preclinical studies, NOP receptor is implicated in regulation of
pain, anxiety and depression, drug abuse, feeding, learning/memory, and motor activity.
Since the time of cloning the receptor and identification of endogenous ligand, numerous
compounds have been designed targeting this receptor. However, there are no PET radioligands
currently available to study NOP distribution and activity in humans. We wish to test a newly
developed PET radioligand, [(11)C]NOP-1A to study the role of NOP receptors in humans.
The purpose of this protocol is (1) to perform brain imaging using [(11)C]NOP-1A in healthy
volunteers to characterize the brain uptake and distribution (2) to perform whole body PET
studies in healthy volunteers in order to estimate radiation absorbed doses for
[(11)C]NOP-1A, (3) to perform brain test-retest studies in healthy volunteers in order to
further examine the precision of the measurement of receptor binding and to determine optimal
parameters for future experiments using [(11)C]NOP-1A, and, (4) to compare [(11)C]NOP-1A
concentrations in artery and vein of healthy volunteers to assess the feasibility of
replacing the arterial line with a less invasive venous line for brain scans.
Successful development of a PET radioligand to image NOP receptor will have a strong impact
on further understanding and clinical management of neuropsychiatric disorders that are
mediated by opioid receptor system. Future experiments will include studies on any relevant
neuropsychiatric disorder.
1994 before identifying the endogenous ligand. Within a year, endogenous ligand was
identified and soon many ligands were developed and evaluated in vitro and in vivo for NOP
receptor distribution and activity. NOP receptor is widely distributed in brain, spinal cord
and in peripheral organs such as heart, lungs, kidney, intestine and liver. Being a G-protein
coupled receptor, its activation leads to changes in intracellular signal transduction
mediated by adenylyl cyclase, Ca(2+) and K(+) ion channels, mitogen-activated kinase and
phospholipase C. Based on preclinical studies, NOP receptor is implicated in regulation of
pain, anxiety and depression, drug abuse, feeding, learning/memory, and motor activity.
Since the time of cloning the receptor and identification of endogenous ligand, numerous
compounds have been designed targeting this receptor. However, there are no PET radioligands
currently available to study NOP distribution and activity in humans. We wish to test a newly
developed PET radioligand, [(11)C]NOP-1A to study the role of NOP receptors in humans.
The purpose of this protocol is (1) to perform brain imaging using [(11)C]NOP-1A in healthy
volunteers to characterize the brain uptake and distribution (2) to perform whole body PET
studies in healthy volunteers in order to estimate radiation absorbed doses for
[(11)C]NOP-1A, (3) to perform brain test-retest studies in healthy volunteers in order to
further examine the precision of the measurement of receptor binding and to determine optimal
parameters for future experiments using [(11)C]NOP-1A, and, (4) to compare [(11)C]NOP-1A
concentrations in artery and vein of healthy volunteers to assess the feasibility of
replacing the arterial line with a less invasive venous line for brain scans.
Successful development of a PET radioligand to image NOP receptor will have a strong impact
on further understanding and clinical management of neuropsychiatric disorders that are
mediated by opioid receptor system. Future experiments will include studies on any relevant
neuropsychiatric disorder.
- INCLUSION CRITERIA:
Healthy Volunteers:
Subjects must be adults between 18-50 years old.
Subjects must be able and willing to give written informed consent.
EXCLUSION CRITERIA:
Current psychiatric illness or severe systemic disease based on history and physical exam.
If women, pregnancy or breast feeding (betaHCG will be measured in all female patients
within 24 hours of scan and must be negative)
Clinically significant laboratory abnormalities.
Serious medical problems including but not limited to chronic neurological disease such as
multiple sclerosis, autoimmune diseases or any cardiopulmonary disease.
Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes.
Recent exposure to radiation (i.e., PET from other research) which when combined with this
study would be above the allowable limits.
Positive urine drug screen at screening.
Inability to lie flat on camera bed for about 2.5 hours
Subjects who have metallic foreign bodies that would be affected by the MRI magnet, or fear
of enclosed spaces likely to make the subject unable to undergo an MRI scan.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
